173 related articles for article (PubMed ID: 37674872)
21. A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.
Gage MM; Rosman M; Mylander WC; Giblin E; Kim HS; Cope L; Umbricht C; Wolff AC; Tafra L
Clin Breast Cancer; 2015 Dec; 15(6):467-72. PubMed ID: 26072275
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
23. Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Kwon MJ; Lee JE; Jeong J; Woo SU; Han J; Kang BI; Kim JE; Moon Y; Lee SB; Lee S; Choi YL; Kwon Y; Song K; Gong G; Shin YK
Front Oncol; 2019; 9():667. PubMed ID: 31404265
[No Abstract] [Full Text] [Related]
24. Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.
Al-Zawi ASA; Yin SL; Aladili Z
Contemp Oncol (Pozn); 2022; 26(2):139-143. PubMed ID: 35903213
[TBL] [Abstract][Full Text] [Related]
25. Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx.
Chiru ED; Oseledchyk A; Schoetzau A; Kurzeder C; Mosimann R; Vetter M; Grašič Kuhar C
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201405
[TBL] [Abstract][Full Text] [Related]
26. A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning.
Kim I; Choi HJ; Ryu JM; Lee SK; Yu JH; Kim SW; Nam SJ; Lee JE
Eur J Surg Oncol; 2019 Feb; 45(2):134-140. PubMed ID: 30348602
[TBL] [Abstract][Full Text] [Related]
27. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
28. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
29. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
[TBL] [Abstract][Full Text] [Related]
30. Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Walter VP; Taran FA; Wallwiener M; Bauer A; Grischke EM; Walter CB; Hahn M; Brucker SY; Hartkopf AD
Geburtshilfe Frauenheilkd; 2020 Jun; 80(6):619-627. PubMed ID: 32565552
[No Abstract] [Full Text] [Related]
31. Young Age as a Predictor of Chemotherapy Recommendation and Treatment in Breast Cancer: A National Cancer Database Study.
Graham E; Bennett K; Boselli D; Hecksher A; Schepel C; White RL; Hadzikadic-Gusic L
J Surg Res; 2024 Apr; 296():155-164. PubMed ID: 38277952
[TBL] [Abstract][Full Text] [Related]
32. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
33. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
Whitney J; Corredor G; Janowczyk A; Ganesan S; Doyle S; Tomaszewski J; Feldman M; Gilmore H; Madabhushi A
BMC Cancer; 2018 May; 18(1):610. PubMed ID: 29848291
[TBL] [Abstract][Full Text] [Related]
34. The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients.
Onoda T; Yamauchi H; Yagata H; Tsugawa K; Hayashi N; Yoshida A; Suzuki K; Sakurai O; Nakamura S
Breast Cancer; 2015 Jul; 22(4):406-12. PubMed ID: 24081457
[TBL] [Abstract][Full Text] [Related]
35. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
Rizki H; Hillyar C; Abbassi O; Miles-Dua S
Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
[TBL] [Abstract][Full Text] [Related]
36. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
37. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.
Song R; Lee DE; Lee EG; Lee S; Kang HS; Han JH; Lee KS; Sim SH; Chae H; Kwon Y; Woo J; Jung SY
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760420
[TBL] [Abstract][Full Text] [Related]
39. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
40. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
